Stryker Corporation is a global leader in medical technologies. The company develops, manufactures, and markets innovative products and services in MedSurg, Neurotechnology, Orthopaedics, and Spine, aiming to improve patient and healthcare outcomes. Stryker serves over 150 million patients annually worldwide. The company sells its products in approximately 75 countries through subsidiaries, branches, and third-party distributors. Key customers include doctors, hospitals, and other healthcare facilities.

MedSurg and Neurotechnology includes surgical equipment, patient handling and emergency medical equipment, endoscopic and communications systems, neurotechnology products (neurosurgical, neurovascular, and craniomaxillofacial implants), and other medical devices. Stryker is a leading competitor in several sub-segments within these categories.

Orthopaedics and Spine focuses on implants for joint replacements (hip, knee, shoulder), trauma and extremities surgeries, and spinal implants. This segment also includes the Mako Robotic-Arm Assisted Surgical System for personalized surgical experiences and specialized instrumentation. Stryker is a major player in the joint replacement, trauma, and spine markets.

Stryker's core values are Integrity, Accountability, People, and Performance, which guide their mission to make healthcare better.

• Employees: 52,000 (as of December 31, 2023)
• Geographic Footprint: Approximately 75 countries
• Headquarters: Portage, Michigan
• Founded: 1941
• Number of locations/facilities: 322 (28 owned, 294 leased, including 43 manufacturing locations)
• Revenue: $20.498 billion (FY2023)
• Market Capitalization: $109.723 billion (as of June 30, 2023)
• Key Subsidiaries/Brands: Wright Medical Group N.V., Cerus Endovascular Limited, Vocera Communications, Inc., Mako Surgical Corp., Mobius Imaging, Cardan Robotics

• CEO: Kevin A. Lobo
• CFO: Glenn S. Boehnlein
• Board Chair: Kevin A. Lobo
• Other Key Executives: Yin C. Becker (Vice President, Chief Corporate Affairs Officer), William E. Berry Jr. (Vice President, Chief Accounting Officer), M. Kathryn Fink (Vice President, Chief Human Resources Officer), Robert S. Fletcher (Vice President, Chief Legal Officer), Viju S. Menon (Group President, Global Quality and Operations), J. Andrew Pierce (Group President, MedSurg and Neurotechnology), Spencer S. Stiles (Group President, Orthopaedics and Spine)

Additional background on tenure and experience is not provided in the 10K filing.

• Annual Revenue: $20.498 Billion (FY2023)
• Net Income: $3.165 Billion (FY2023)
• Market Cap: $109.723 billion (as of June 30, 2023)
• Total Assets: $39.912 billion (FY2023)
• Number of Employees: 52,000 (as of December 31, 2023)
• Key Financial Highlights: Net sales increased 11.1% as reported and 11.6% in constant currency. Net earnings per diluted share were $8.25. Adjusted net earnings were $4.066 billion, and adjusted net earnings per diluted share were $10.60, representing growth of 13.5%.

Stryker offers a wide range of medical technology products and services across various categories:

• MedSurg: This segment includes surgical equipment and navigation systems (Instruments), endoscopic and communications systems and reprocessed and remanufactured medical devices (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and workflow solutions (Medical).
• Neurotechnology: This category encompasses neurosurgical, neurovascular, and craniomaxillofacial implant products, including products for minimally invasive endovascular procedures, traditional brain surgery, and stroke treatment.
• Orthopaedics: This segment focuses on implants for joint replacements (hip, knee, shoulder), trauma and extremities surgeries, and the Mako Robotic-Arm Assisted Surgical System.
• Spine: This category includes cervical and thoracolumbar spinal implant systems, minimally invasive and interbody systems, and digital health solutions.

Specific revenue contributions for individual products or services are not available in the 10-K.

Stryker operates under two reportable business segments:

• MedSurg and Neurotechnology: Revenue of $11.836 billion (FY2023), representing 58% of total revenue.
• Orthopaedics and Spine: Revenue of $8.662 billion (FY2023), representing 42% of total revenue.

Stryker's primary strategic priorities include:

• Achieving sales growth at the high end of the medical technology industry.
• Maintaining a long-term capital allocation strategy focused on acquisitions, dividends, and share repurchases.
• Driving innovation in new product development and improving existing products.
• Focusing on quality and service to differentiate themselves in the competitive market.

Stryker operates in the highly competitive medical technology industry. The company faces competition from both local and global companies. Key competitors vary by product line and include Zimmer Biomet Holdings, Inc., Medtronic plc, Johnson & Johnson, Smith & Nephew plc, and others. The industry is characterized by continuous research and development, requiring substantial investment. Key market trends impacting Stryker include increasing governmental regulation, cost containment initiatives, and pricing pressures.

• Supply Chain Disruptions: Stryker's global supply chain is susceptible to shortages and price increases of raw materials, components, and third-party services, which could impact operating costs and product competitiveness.
• Pricing Pressures: Cost containment measures and other factors put pressure on Stryker's pricing, potentially affecting profitability.
• Intense Competition: The medical technology industry is highly competitive, with constant pressure to innovate and develop new products to maintain market share.
• Global Operations Risks: Stryker's global presence exposes them to various risks, including changes in reimbursement, regulatory requirements, political and economic instability, and supply chain security threats.
• Cybersecurity Risks: Reliance on information technology systems exposes Stryker to potential data breaches and disruptions, which could compromise sensitive data and business operations.